159 related articles for article (PubMed ID: 38686383)
21. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
22. Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer.
Huang Y; Liu Z; He L; Chen X; Pan D; Ma Z; Liang C; Tian J; Liang C
Radiology; 2016 Dec; 281(3):947-957. PubMed ID: 27347764
[TBL] [Abstract][Full Text] [Related]
23. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
24. Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy.
Chang R; Qi S; Wu Y; Yue Y; Zhang X; Qian W
Cancer Imaging; 2023 Oct; 23(1):101. PubMed ID: 37867196
[TBL] [Abstract][Full Text] [Related]
25. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.
Zheng X; Shao J; Zhou L; Wang L; Ge Y; Wang G; Feng F
Ther Innov Regul Sci; 2022 Jan; 56(1):155-167. PubMed ID: 34699046
[TBL] [Abstract][Full Text] [Related]
26. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
Wang L; Ren Z; Yu B; Tang J
J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
[TBL] [Abstract][Full Text] [Related]
27. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.
Wang J; Wang J; Huang X; Zhou Y; Qi J; Sun X; Nie J; Hu Z; Wang S; Hong B; Wang H
BMC Med Imaging; 2024 Feb; 24(1):45. PubMed ID: 38360550
[TBL] [Abstract][Full Text] [Related]
28. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features.
Khorrami M; Jain P; Bera K; Alilou M; Thawani R; Patil P; Ahmad U; Murthy S; Stephans K; Fu P; Velcheti V; Madabhushi A
Lung Cancer; 2019 Sep; 135():1-9. PubMed ID: 31446979
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
[TBL] [Abstract][Full Text] [Related]
30. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
31. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
32. Peritumoral radiomics features predict distant metastasis in locally advanced NSCLC.
Dou TH; Coroller TP; van Griethuysen JJM; Mak RH; Aerts HJWL
PLoS One; 2018; 13(11):e0206108. PubMed ID: 30388114
[TBL] [Abstract][Full Text] [Related]
33. Prediction and verification of survival in patients with non-small-cell lung cancer based on an integrated radiomics nomogram.
Li R; Peng H; Xue T; Li J; Ge Y; Wang G; Feng F
Clin Radiol; 2022 Mar; 77(3):e222-e230. PubMed ID: 34974912
[TBL] [Abstract][Full Text] [Related]
34. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
PeerJ; 2022; 10():e14566. PubMed ID: 36540802
[TBL] [Abstract][Full Text] [Related]
35. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
36. Radiomics of
Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
[TBL] [Abstract][Full Text] [Related]
37. Radiomics-based prediction of response to immune checkpoint inhibitor treatment for solid cancers using computed tomography: a real-world study of two centers.
Yu Y; Bai Y; Zheng P; Wang N; Deng X; Ma H; Yu R; Ma C; Liu P; Xie Y; Wang C; Chen H
BMC Cancer; 2022 Nov; 22(1):1241. PubMed ID: 36451109
[TBL] [Abstract][Full Text] [Related]
38. Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pretreatment glioblastoma: Prognostic value of MRI-based radiomics.
Choi Y; Ahn KJ; Nam Y; Jang J; Shin NY; Choi HS; Jung SL; Kim BS
Eur J Radiol; 2019 Nov; 120():108642. PubMed ID: 31546124
[TBL] [Abstract][Full Text] [Related]
39. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
40. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
